More Videos
SPECIAL REPORT
MOST SHARED
- 'Peak Oil' Closer Than IEA Forecasts Show: Report
- AIG Moving Toward Repaying Bailout: Moody's
- Pociask: In The Electronics War Does The Consumer Really Win?
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- News Corp. May Pull Content From Google Searches
- Health-Care Reform Does Little To Contain Costs: Analysts
- Justices Poke Fun at Patents for the Abstract
- Home Prices Sank Further In Most Parts of US in 3rd Quarter
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Passive Job Search Strategies
- Back Off, Regulators!
- America Is On Sale
- Warren Buffett and the Crisis: 'Brilliant Moves Interspersed with Some Surprising Errors'
- Schork Oil Outlook: More Strength in Crude
- Chrysler Makes Smart Call Staying Unplugged—For Now
- Your Next Move: Thriving and Managing in Limbo
- Home Prices Decline Further In Most Parts of US
- Mortgage Modification Program Shows Improvement
- Dodd Proposes Major Financial Reform Overhaul
- Fed Officials Warn About Job Growth, Weak Recovery
- Housing Still Has 'a Ways to Go': Wilbur Ross Exec
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- New Lows for Stocks Next Year: Equities Bear
- AIG Moving Toward Repaying Bailout: Moody's
- 'Peak Oil' Closer Than IEA Forecasts Show: Report
RSS FEED
Pharma's Market
Text Size 
 |
First, Johnson & Johnson ponied up nearly a billion bucks for Cougar Biotech. And it did it before seeing late-stage test results to determine if CGRB's prostate cancer drug extends lives, which is the new gold standard in oncology treatments. That might have raised a few eyebrows. But it's a relatively small gamble for a company as big as JNJ. And one source tells me JNJ may have quickly pulled the trigger because several other companies were courting Cougar. As that person said, "There's a lot of hand-wringing and crying over spilled milk going on." In other words, you snooze, you lose.
Then, today Sanofi-Aventis is hooking up with Exelixis in a deal that could be worth more than a billion dollars over time on two cancer drugs in early-stage clinical trials.
EXEL's CEO, George Scangos, was pretty forthcoming about big pharma's interest. On the conference call, he revealed that almost every other major drug company kicked the tires. Exelixis recently did a similar partnership with Bristol-Myers Squibb. And Scangos said the company is in "additional deal discussions" on other stuff in its drug development pipeline. But he added the company is in the enviable position of sitting on a sizeable pile of cash right now and doesn't need to do another deal. Talk about leverage!
Of course, when there's a confluence of deal activity like this everyone starts wondering who's next? There's always a list of usual suspects in oncology including OSI Pharmaceuticals and Onyx, just to name a couple, but these days it seems that names flying under a lot of investors' radars are getting into the game. It's worth noting that the two most recent deals were both done before the big ASCO (American Society of Clinical Oncology) meeting, which starts tomorrow in Orlando.
That's where biopharma struts its stuff. There's not as much big stuff at ASCO this year as there has been in recent years, but it's apparently enough to get big pharma to open its checkbook.
And it's enough to get our attention. I'll be reporting live from ASCO next Monday and, for the first time (provided I don't get kicked out again), our camera position will be inside the air-conditioned convention hall.
I'm also hoping with Monday's deadline looming that a General Motors bankruptcy filing doesn't blow out our coverage.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes